Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

CAD may lead to an 8 percent increase in adenoma detection rate and 2 percent increase in detection rate of advanced colorectal neoplasia.